| Literature DB >> 14975133 |
Chien-Hsiun Chen1, Chee Jen Chang, Wei-Shiung Yang, Chun-Liang Chen, Cathy S J Fann.
Abstract
BACKGROUND: In the analysis of complex traits such as fasting plasma glucose levels, researchers often adjust the trait for some important covariates before assessing gene susceptibility, and may at times encounter confounding among the covariates and the susceptible genes. Previously, the tree-based method has been employed to accommodate the heterogeneity in complex traits. In this study, we performed a genome-wide screen on fasting glucose levels in the offspring generation of the Framingham Heart Study provided by the Genetic Analysis Workshop 13. We defined one quantitative trait and converted it to a dichotomous trait based on a predetermined cut-off value, and performed association analyses using regression and classification trees for the two traits, respectively. A marker was interpreted as positive if at least one of its alleles exhibited association in both analyses. Our purpose was to identify candidate genes susceptible to fasting glucose levels in the presence of other covariates. The covariates entered in the analysis including sex, body mass index, and lipids (total plasma cholesterol, high density lipoprotein cholesterol, and triglycerides) of the subjects, and those of their parents.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14975133 PMCID: PMC1866503 DOI: 10.1186/1471-2156-4-S1-S65
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Figure 1A proportion of an optimal tree from classification tree Decision node criteria: 1. BMI: average BMI across-section 2. HBP: ever hypertension in all sections 3. MTG: average maternal triglycerides 4. Allele 266 of D16S2620 Definition of classes: Class 0, glucose levels < 110 mg/dl in all section; Class 1, at least one observed fasting glucose levels >110 mg/dl.
Positive markers found in the analyses using classification and regression trees
| Chr | Marker | Marker Alias | Position | Previous Reports |
| 1 | D1S1665 | GATA61A06 | 1p31.1 | Amylase, salivary, Pancreatic (1p21), facilitated glucose transporter (1p31-35), agiopoietin-like 3 (1p31) |
| 2 | D2S2952 | GATA116B01 | 2p25.1 | Glucokinase regulatory protein (2p23), Alstrom syndrome (2p13), serum levels of leptin (2p21), hexokinase 2 (2p12), eukaryote translation initiation factor 2-α kinase 3 (Wolcott-Rallison syndrome, 2p21) |
| 6 | D6S474 | GATA31 | 6q21 | IDDM 1 (6q21) IDDM5 (6q24-27), IDDM8 (6q25-27), IDDM15, transient neonatal diabetes mellitus (6q24), pleomorphic adenoma gene-like 1 (6q24-26), phosphodiesterase 1 (6q22-23) |
| 11 | D11S1981 | GATA48E02 | 11p15.1 | HRAS (11p14.1), INS (11p14.1), MODY1 (11p15.5), phosphodiesterase 3B (11p15), SUR1 (11p15.1), Kir6.2 (11p15.1) |
| 16 | D16S3396 | ATA55A11 | 16q12.1 | RRAD (16q22) |
| D16S3253 | GATA22F09 | 16q12.2 | ||
| D16S2620 | GATA67G11 | |||
| 18 | D18S542 | GATA11A06 | 18p11.21 | |
| 19 | D19S254 | Mfd238 | 19q13.43 | Glycogen synthase 1 (muscle)(19q13.3), ApoCIII (19q13.2), Dystrophia Myotonica 1 (19q13.2-13.3), AKT2 (19q13.1-13.2), TGFβ1 (19q13.1), Glycogen synthase kinase 3A (19q13.1-13.2) |